Enveric Biosciences 대차 대조표 상태

재무 상태 기준 확인 4/6

Enveric Biosciences 의 총 주주 지분은 $4.0M 이고 총 부채는 $0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 $4.8M 및 $839.2K 입니다.

주요 정보

부채 비율

US$0

부채

이자 보상 비율	n/a
현금	US$3.11m
주식	US$3.95m
총 부채	US$839.17k
총 자산	US$4.79m

최근 재무 상태 업데이트

Recent updates

재무 상태 분석

단기부채: SLZA 의 단기 자산 ( $4.3M )이 단기 부채( $839.2K ).

장기 부채: SLZA 에는 장기 부채가 없습니다.

부채 대 자본 내역 및 분석

부채 수준: SLZA 부채가 없습니다.

부채 감소: SLZA 현재 부채가 없지만 해당 기간에 대한 데이터가 없기 때문에 5년 전과 비교할 수 없습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: SLZA 현재 무료 현금 흐름을 기준으로 1년 미만의 cash runway를 보유하고 있습니다.

예측 현금 활주로: 무료 현금 흐름이 매년 30.9 %의 역사적 비율로 계속 감소할 경우 SLZA 의 현금 활주로는 1년 미만입니다.

Enveric Biosciences 대차 대조표 상태

재무 상태 기준 확인 4/6

주요 정보

최근 재무 상태 업데이트

The Listing Qualifications Department of the Nasdaq Stock Market Issues A Determination to Enveric Biosciences

The Listing Qualifications Department of the Nasdaq Stock Market Issues A Determination to Enveric Biosciences

Enveric Biosciences Regains Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(b)(1)

Enveric Biosciences Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Marketplace Rule 5550(a)(2)

Enveric Biosciences Receives Notice from the Nasdaq Stock Market

Enveric Biosciences Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Recent updates

Enveric Biosciences Announces Completion of Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-Like Behavior

The Listing Qualifications Department of the Nasdaq Stock Market Issues A Determination to Enveric Biosciences

The Listing Qualifications Department of the Nasdaq Stock Market Issues A Determination to Enveric Biosciences

New major risk - Financial position

Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003

New major risk - Financial position

Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to Be Dosed Orally

New major risk - Share price stability

Enveric Biosciences Regains Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(b)(1)

Enveric Biosciences Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Marketplace Rule 5550(a)(2)

New major risk - Financial position

High number of new and inexperienced directors

Enveric Biosciences, Inc., Annual General Meeting, May 28, 2024

New major risk - Shareholder dilution

Enveric Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $0.322453 million.

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders

Enveric Biosciences Receives Notice from the Nasdaq Stock Market

New major risk - Share price stability

Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series

Enveric Biosciences Selects Development Candidates from Evm301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds

Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry

Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry

Enveric Biosciences Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373

Enveric Biosciences, Inc., Annual General Meeting, Nov 02, 2023

Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program

High number of new and inexperienced directors

Enveric Biosciences, Inc. Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373

Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373

Enveric Biosciences, Inc. Announces Development of Phase 1-Ready Formulation for EB-373 and Initiation of Scaled Up Manufacturing

Enveric Biosciences, Inc. Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health Disorders

Enveric Biosciences, Inc. Receives Notice of Allowance from Uspto for Novel Prodrug of Psilocin

High number of new and inexperienced directors

High number of new and inexperienced directors

Enveric Biosciences, Inc. Advances Lead Candidate for the Treatment of Anxiety Disorders to IND-Enabling Studies

Enveric Biosciences, Inc., Annual General Meeting, Oct 28, 2022

Enveric Biosciences, Inc. Appoints Robert Dickey IV as Chief Financial Officer

Enveric Biosciences, Inc. Regains Compliance with Listing Rule 5550(a)(2) Letter from the Listing Qualifications Department of Nasdaq

Enveric Biosciences, Inc. Appoints New Independent Directors

Enveric Biosciences, Inc. announced that it expects to receive $5 million in funding

Enveric Biosciences Announces Formation of Scientific Advisory Board to Drive Further Growth of Next-Generation Mental Health Medicines

Enveric Biosciences, Inc. Announces Appointment of Frank Pasqualone to the Board of Directors

Enveric Biosciences Announces Management Appointments

High number of new and inexperienced directors

Enveric Biosciences, Inc. Expands Portfolio of Drug Development Candidates and Files New Provisional Patent Application

Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules

Enveric Biosciences, Inc. announces development of EV104a and EV104b

Enveric Biosciences, Inc. (NasdaqCM:ENVB) entered into a definitive agreement to acquire MagicMed Industries Inc.

Enveric Biosciences, Inc. announced delayed annual 10-K filing

Enveric Biosciences, Inc. Appoints Dr. Douglas D. Lind to Company's Board of Directors

Enveric Biosciences, Inc. (NasdaqCM:ENVB) completed the acquisition of Exclusive and perpetual license for Diverse Biotech novel molecules from Diverse Biotech, Inc.

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

현금 런웨이 분석

건강한 기업 발견하기